At $1.15 a share, the offering is being done on a "best efforts" basis. Subject to usual circumstances, the business ...

Glucotrack has cleared the first human clinical study of its long-term continuous glucose monitoring implant, designed to ...

RUTHERFORD, N.J. - Glucotrack, Inc. (NASDAQ:GCTK), a medical device company specializing in diabetes care technology, has ...

The company’s system is placed in the subclavian vein, a blood vessel that runs under the collar bone bringing deoxygenated ...

This study represents the first real-time, continuous blood glucose monitor (CBGM) placed in the subclavian vein, offering the potential for direct blood glucose measurement without the limitations ...

Rutherford, NJ., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical technology company focused on the design, development, and ...

Glucotrack has successfully completed its first in-human clinical study for the first real-time, continuous blood glucose monitor (CBGM) placed in the subclavian vein.

Glucotrack’s Common Stock will continue to trade on the Nasdaq Capital Market (“Nasdaq”) under the symbol “GCTK”. The new CUSIP number for the Common Stock following the Reverse Stock Split will be ...

Glucotrack, Inc. has announced the successful completion of its first human clinical study for a continuous blood glucose monitor (CBGM), which is uniquely placed in the subclavian vein for real ...

Glucotrack, Inc. (Nasdaq: GCTK) disclosed a significant move within its capital structure. This Delaware corporation specializing in medical devices made public a press release involving a 1-for-20 ...

RUTHERFORD, N.J., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on ...

RUTHERFORD, N.J., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on the ...